Example: Heart Attack
Clinical Trials on Human T-cell Leukemia Virus Type 2
Total 0 results
We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
Medical Conditions
- COVID-19
- ARB
- Aneurismal Subarachnoid Hemorrhage
- Central Nervous System (CNS) Demyelinating Disease
- Complications Wounds
- Excessive Alcohol Consumption
- Focus of the Study is to Promote Healthy Hearing
- Neovascular Age-elated Macular Degeneration (Wet AMD)
- Parasitology
- Prolonged DAPT in ACS Patients With Hisk of Both Ischemic and Hemorrhage
- Squamous Cell Carcinoma to the Head and Neck
- Stage A Adult Primary Liver Cancer (BCLC)
- Tuberculosis, Multidrug-Resistant
- Vesicoureteral Reflux
- View Full List
Sponsors and Collaborators
- Albertslund Kommune
- Ascension South East Michigan
- Blake Lesselroth
- Bucheon Sejong Hospital
- Department of Surgery, Lasarettet, Östersund, Sweden
- Ellern Mede Barnet
- Life Research Technologies GmbH
- MD Stem Cells
- Medistra Hospital, University of Indonesia
- PREDIT Go4
- Rocky Mountain MS Research Group, LLC
- Scott Kollins, PhD
- University Hospital Copenhagen
- View Full List
Drug Interventions
- 0.4% Retinol Cream
- CB4211 Dose 1
- Comparator: montelukast sodium
- Exenatide Microspheres for Injection
- Fosbretabulin Tromethamine
- Gemtuzumab Ozogamicin (Mylotarg)
- Gliadel Wafer
- Immunoscintigraphy with radiolabeled Cimzia®.
- JNJ-47910382 90 mg
- Pemafibrate
- Riluzole
- crofelemer
- normal saline 0.5ml
- View Full List
Conditions
Rare Diseases
Drug Interventions
Dietary Supplements
Sponsor/Collaborators
Locations